Matinas Biopharma Holdings is a clinical-stage
biopharmaceutical company focused on the development of safe and effective
broad spectrum antifungal and anti-bacterial therapeutics for the treatment of
serious and life-threatening infections. The company’s proprietary, disruptive
technology utilizes lipid-crystal nano-particle cochleate to nano-encapsulate
existing drugs, making them safer, more tolerable, less toxic and orally
available. Matinas’s lead drug candidate, MAT2203, is an orally administered, encochleated
formulation of amphotericin B, an antifungal drug currently used intravenously
to treat a variety of fungal infections.
Last month, Matinas took a significant step in the
development of MAT2203 when it announced that the U.S. Food and Drug Administration
(FDA) had designated the candidate as a qualified infectious disease product
(QIDP) with fast track status. These designations make the candidate eligible
for priority review and expedited development processes in the future, as well
as providing up to five years of additional marketing exclusivity following FDA
approval.
In a phase IA clinical study, MAT2203 demonstrated a
positive safety and tolerability profile with no serious or dose-related
adverse events reported. In collaboration with the National Institutes of
Health/National Institute of Allergy and Infectious Disease, the company plans
to commence a phase IIA clinical study of MAT2203 in patients with refractory
mucocutaneous candidiasis in the coming weeks.
“While the antifungal amphotericin B has demonstrated little
or no resistance in clinical practice, it currently has limited treatment use
in fungal infections due to severe toxicity issues,” Roelof Rongen, president
and chief executive officer of Matinas, stated in a news release. “We believe
MAT2203 has the potential to bring a much needed effective, broad-spectrum and
significantly less toxic antifungal to at-risk patients with invasive and
resistant fungal infections.”
In addition to MAT2203, Matinas’s development pipeline
includes MAT2501, an orally-administered formulation of amikacin currently
being developed for the treatment of gram-negative and intracellular bacterial
infections; and MAT9001, a prescription-only omega-3 fatty acid-based
composition being developed for the treatment of hypertriglyceridemia.
Through the utilization of its proprietary lipid-crystal
nano-particle cochleate formulation technology, Matinas is in a favorable
strategic position to become a leader in the safe and effective delivery of
anti-infective therapies. Look for the company to continue leaning on the
cumulative multi-decade pharmaceutical development and commercialization
experience of its management team in order to make continued strides toward the
commercialization of its promising developmental candidates.
For more information, visit www.matinasbiopharma.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
